Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
NCT04855136
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
21
Enrollment
INDUSTRY
Sponsor class
Stopped
Business objectives have changed
Conditions
Multiple Myeloma
Interventions
BIOLOGICAL:
BB2121
DRUG:
CC-220
DRUG:
BMS-986405
Sponsor
Celgene